Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a Healthcare company (Biotechnology) with a market capitalization of $258M. The Maz Rating grades it against the other companies in its sector.
Allogene Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.74, Allogene Therapeutics, Inc. trades at 55.3x sales and 0.7x book value. Over the last twelve months it generated about $5M of revenue and a net loss of $219M. It runs an operating margin of -4099.3% and a net margin of -3760.0%. It shows return on equity of -49.8%, return on invested capital of -40.2% and a free cash flow yield of -42.3%. On the balance sheet: a debt-to-equity ratio of 0.17 and a current ratio of 7.79. Over the past 52 weeks the share price ranged from $0.74 to $4.46, with a beta of 0.48.
Allogene Therapeutics, Inc. does not currently pay a dividend.
30 Wall Street analyst ratings cover the stock: 19 Buy, 10 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.